0001004878-17-000202.txt : 20170831 0001004878-17-000202.hdr.sgml : 20170831 20170831171819 ACCESSION NUMBER: 0001004878-17-000202 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170831 ITEM INFORMATION: Material Modifications to Rights of Security Holders FILED AS OF DATE: 20170831 DATE AS OF CHANGE: 20170831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 171063974 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 8-K 1 form8kitem303ddeewar8-17.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 29, 2017 CEL-SCI CORPORATION -------------------------------------- (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 -------------------- ------------------- ---------------- (State or other jurisdiction (Commission File No.) (IRS Employer of incorporation) Identification No.) 8229 Boone Boulevard, Suite 802 Vienna, Virginia 22182 -------------------------------------- (Address of principal executive offices, including Zip Code) Registrant's telephone number, including area code: (703) 506-9460 N/A -------------------------------------- (Former name or former address if changed since last report) Item 3.03. Material Modification to Rights of Security Holders. On August 29, 2017 the Company extended the expiration date of its Series DD and Series EE warrants until the close of business on December 1, 2017. The Series DD and Series EE warrants were issued as part of a financing on December 8, 2016. As a result of the reverse stock split approved by the Company's shareholders and adopted by the Company's directors: o the holders of the Series DD warrants are entitled to purchase 1,360,960 shares of the Company's common stock at an exercise price of $4.50 per share; and o the holders of the Series EE warrants are entitled to purchase 1,360,960 shares of the Company's common stock at an exercise price of $4.50 per share. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 31, 2017 CEL-SCI CORPORATION By: /s/ Patricia Prichep ----------------------------------- Patricia Prichep Senior Vice President of Operations